 |
| |
 |
| |
 |
| |
 |
| |
 |
MacroStat, Inc.
Delaware Technology Park
One Innovation Way
Suite 302
Newark, DE 19711, USA
Phone: (302) 438-2889
Fax: (302) 239-7442
498 Guoshoujing Road
Suite 11301-11304
Shanghai, 201203, China
Phone: (86) 21-50276030
Fax: (86) 21-50807377
www.macrostat.com.cn
info@macrostat.com
Delaware Technology Park
One Innovation Way
Suite 302
Newark, DE 19711, USA
Phone: (302) 438-2889
Fax: (302) 239-7442
498 Guoshoujing Road
Suite 11301-11304
Shanghai, 201203, China
Phone: (86) 21-50276030
Fax: (86) 21-50807377
www.macrostat.com.cn
info@macrostat.com
Bing Zhang, Ph.D.
President
Dr. Zhang has a Ph.D. in Statistics and a M.S. in Computer Science
from the University of Kentucky. He has seventeen years of
experience in line management and statistical analyses for
pharmacokinetic (PK) and Phase I-IV clinical trials as well as
integrated summaries of safety (ISS) and efficacy (ISE) for new
drug applications (NDA) in various therapeutic areas such as pain
control, oncology, cardiovascular, respiratory, psychotic disorders,
anti-viral, antibiotic, and blood substitute. Before founding
MacroStat Inc., he held the position of Associate Director of
Biostatistics at a biotech company, various leadership positions for
statistics and SAS programming groups at a large pharmaceutical
company, and Senior Statistician at a CRO. Dr. Zhang has
extensive experience in the development of clinical development
plans, clinical trial protocols, statistical analysis plans, and clinical
trial reports; and in the preparation of multiple NDA submissions.
He has received multiple commendations for his statistical work.
He also designed and developed a PC-based computer-aided
NDA (CANDA) that was submitted to Cardio-Renal division and
resulted in acceleration of NDA approval.
President
Dr. Zhang has a Ph.D. in Statistics and a M.S. in Computer Science
from the University of Kentucky. He has seventeen years of
experience in line management and statistical analyses for
pharmacokinetic (PK) and Phase I-IV clinical trials as well as
integrated summaries of safety (ISS) and efficacy (ISE) for new
drug applications (NDA) in various therapeutic areas such as pain
control, oncology, cardiovascular, respiratory, psychotic disorders,
anti-viral, antibiotic, and blood substitute. Before founding
MacroStat Inc., he held the position of Associate Director of
Biostatistics at a biotech company, various leadership positions for
statistics and SAS programming groups at a large pharmaceutical
company, and Senior Statistician at a CRO. Dr. Zhang has
extensive experience in the development of clinical development
plans, clinical trial protocols, statistical analysis plans, and clinical
trial reports; and in the preparation of multiple NDA submissions.
He has received multiple commendations for his statistical work.
He also designed and developed a PC-based computer-aided
NDA (CANDA) that was submitted to Cardio-Renal division and
resulted in acceleration of NDA approval.
Our Team
MacroStat, Inc.
Helen Yin, M.S.
Managing Director of MacroStat China
Ms. Yin has a M.S. in Biostatistics from the University of
Massachusetts. She has more than fifteen years of experience in
management and statistical analyses in the pharmaceutical
industry worldwide, including eight years in United States and
sevenyears in China/Asia Region. She has held the positions of
Head of Clinical Support Division of the R&D Department,
Associate Director of Biostatistics, US therapeutic leader for breast
cancer, and other statistical and consulting positions in the
pharmaceutical and CRO companies. She has extensive
experience in multiple IND/NDA submissions in various therapeutic
areas, especially oncology.
Managing Director of MacroStat China
Ms. Yin has a M.S. in Biostatistics from the University of
Massachusetts. She has more than fifteen years of experience in
management and statistical analyses in the pharmaceutical
industry worldwide, including eight years in United States and
sevenyears in China/Asia Region. She has held the positions of
Head of Clinical Support Division of the R&D Department,
Associate Director of Biostatistics, US therapeutic leader for breast
cancer, and other statistical and consulting positions in the
pharmaceutical and CRO companies. She has extensive
experience in multiple IND/NDA submissions in various therapeutic
areas, especially oncology.
